Literature DB >> 17548458

Does one voriconazole breakpoint suit all Candida species?

Maiken Cavling Arendrup, David W Denning, M A Pfaller, D J Diekema, J H Rex.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17548458      PMCID： PMC1933056          DOI： 10.1128/JCM.00412-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  13 in total

1.  Safety of voriconazole and dose individualization.

Authors:  Irja Lutsar; Mike R Hodges; Konrad Tomaszewski; Peter F Troke; Nolan D Wood
Journal:  Clin Infect Dis       Date:  2003-04-15       Impact factor: 9.079

2.  Candidemia in Norway (1991 to 2003): results from a nationwide study.

Authors:  Per Sandven; Lars Bevanger; Asbjørn Digranes; Hanne H Haukland; Turid Mannsåker; Peter Gaustad
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Patricia Ribaud; Noel Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Journal:  Clin Infect Dis       Date:  2002-01-22       Impact factor: 9.079

4.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  C Viscoli; C Girmenia; A Marinus; L Collette; P Martino; B Vandercam; C Doyen; B Lebeau; D Spence; V Krcmery; B De Pauw; F Meunier
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

5.  Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers.

Authors:  Arnaldo L Colombo; Marcio Nucci; Benjamin J Park; Simone A Nouér; Beth Arthington-Skaggs; Daniel A da Matta; David Warnock; Juliette Morgan
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  In vivo pathogenicity of eight medically relevant Candida species in an animal model.

Authors:  M Arendrup; T Horn; N Frimodt-Møller
Journal:  Infection       Date:  2002-10       Impact factor: 3.553

7.  Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

Authors:  D J Diekema; S A Messer; A B Brueggemann; S L Coffman; G V Doern; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

8.  Adverse reactions to voriconazole.

Authors:  Aileen E Boyd; Simon Modi; Susan J Howard; Caroline B Moore; Brian G Keevil; David W Denning
Journal:  Clin Infect Dis       Date:  2004-09-23       Impact factor: 9.079

9.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

10.  Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.

Authors:  David S Krause; John Reinhardt; Jose A Vazquez; Annette Reboli; Beth P Goldstein; Michele Wible; Timothy Henkel
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
View more
  5 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom.

Authors:  Andrew M Borman; Adrien Szekely; Michael D Palmer; Elizabeth M Johnson
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

3.  Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

4.  Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2010-12-15       Impact factor: 5.948

5.  Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.

Authors:  Michael A Pfaller; Shawn A Messer; Leah N Woosley; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-05-29       Impact factor: 5.948
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.